Repaglinide Tablet
Product Images NDC 71335-2598

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Repaglinide (NDC 71335-2598). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352598)

Repaglinide Tablets USP 2 mg oral tablets label showing the product name, strength, and quantity of 30 tablets. The label includes NDC 71335-2598-1, manufacturer Macleods Pharmaceuticals Ltd., and repackager Bryant Ranch Prepack, Inc. Storage instructions and warnings are also present.*

FDA Label Image

505 (Repaglinide Figure 1)

A line graph showing the change in HbA1c (%) over 24 weeks of treatment. The graph compares three groups: Repaglinide plus Pioglitazone, Repaglinide alone, and Pioglitazone alone, with the x-axis representing treatment weeks and the y-axis showing percentage change in HbA1c. The combination group shows the greatest decrease in HbA1c over time.*

FDA Label Image

Str (Repaglinide Str)

Chemical structure of Repaglinide illustrating its molecular framework, including aromatic rings, amide bonds, and other characteristic groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.